Statistik Asas
| CIK | 1642380 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OncoCyte Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 18, 2025 |
As filed with the Securities and Exchange Commission on August 18, 2025 As filed with the Securities and Exchange Commission on August 18, 2025 Registration No. |
|
| August 18, 2025 |
Exhibit 99.2 FIRST AMENDMENT TO THE ONCOCYTE CORPORATION AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN Approved by Shareholders June 27, 2025 This FIRST AMENDMENT TO THE ONCOCYTE CORPORATION AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN (this “Amendment”), effective as of May 14, 2025, is made and entered into by Oncocyte Corporation, a California corporation (the “Company”). Terms used in thi |
|
| August 18, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Insight Molecular Diagnostics Inc. |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-37648 Insig |
|
| August 11, 2025 |
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch Exhibit 99.1 IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch ● Reiterating timelines for FDA submission in 2025 ● Transplant clinical trial has attracted leading transplant hospitals ● Booked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, TENN., August 11, 2025 — Insight Molecular Diagnostics |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Insight Molecular Diagnostics Inc. (Exact name of Registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of incorporation) |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Insight Molecular Diagnostics Inc. (Exact name of Registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of incorporation) (C |
|
| June 17, 2025 |
Third Amended and Restated Bylaws of Insight Molecular Diagnostics Inc. Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF INSIGHT MOLECULAR DIAGNOSTICS INC. (the “Corporation”) ARTICLE I OFFICES Section 1.01 PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at such place within or without the State of California as shall be fixed from time to time by the board of directors, and if no place is fixed by the board of directors, |
|
| June 17, 2025 |
Exhibit 3.1 CERTIFICATE OF OWNERSHIP Joshua Riggs and Peter Hong certify that: 1. They are the Chief Executive Officer and the Secretary, respectively, of Oncocyte Corporation, a California corporation, with California Entity Number 3231738 (the “Corporation”). 2. This Corporation owns 100% of the outstanding shares of Insight Molecular Diagnostics Inc., a California corporation, with California E |
|
| June 17, 2025 |
A letter to our shareholders from iMDx Chief Executive Officer Josh Riggs June 17, 2025 Exhibit 99.2 A letter to our shareholders from iMDx Chief Executive Officer Josh Riggs June 17, 2025 Healthcare is full of uncertainty. Uncertainty for patients – What is going on? Will I get to keep my kidney? Is the drug working? How will I manage? Uncertainty for physicians – Is the transplanted organ healthy? Can anything be done to stop the current course? What should be the next course of tr |
|
| June 17, 2025 |
Oncocyte Changes Name to Insight Molecular Exhibit 99.1 Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville ● New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care ● iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally ● Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, Ju |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Oncocyte Corp Insight Molecular Diagnostics Inc. (Exact name of Registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of inc |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 12, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2025 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-37648 Oncocyte Corporation ( |
|
| May 12, 2025 |
Oncocyte Reports Q1 2025 Results and Business Progress Exhibit 99.1 Oncocyte Reports Q1 2025 Results and Business Progress ● Q1 2025 pharma services revenue of $2.1 million, at 62% gross margin ● Three of the top 10 U.S. transplant centers expected to participate in clinical trial ● Ten globally leading transplant hospitals are now using our GraftAssure research-use-only kits ● To reflect our larger market opportunity, we plan to rename the company in |
|
| April 17, 2025 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 11, 2025 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| April 17, 2025 |
Letter from Marcum LLP dated April 17, 2025. Exhibit 16.1 April 17, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Oncocyte Corporation under Item 4.01 of its Form 8-K dated April 17, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Oncocyte Corporation contained th |
|
| April 8, 2025 |
Oncocyte Corporation 10,606,632 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-286251 PROSPECTUS Oncocyte Corporation 10,606,632 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 10,606,632 shares of our common stock, no par value per share (“common stock”). These 10,606,632 shares of common stock consist of: ● 7,536,706 shares of c |
|
| April 4, 2025 |
Oncocyte Corporation 15 Cushing Irvine, California 92618 Oncocyte Corporation 15 Cushing Irvine, California 92618 April 4, 2025 VIA EDGAR Division of Corporation Finance Office of Life Sciences U. |
|
| March 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 Oncocyte Corporation Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, no par value per share Rule 457(c) 10,606,632 (2) $ 3. |
|
| March 28, 2025 |
As Filed with the Securities and Exchange Commission on March 28, 2025 As Filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 24, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 24, 2025 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| March 24, 2025 |
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts Exhibit 99.1 Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts ● Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million ● GraftAssure RUO assay launched July 2024 ● Signed strategic partner and investor, Bio-Rad Laboratories ● Fully funded clinical kitted product development with $50+ million in equity raises ● Advanced science in transplant; achieved M |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (Exact |
|
| March 24, 2025 |
Exhibit 4.7 DESCRIPTION OF SECURITIES The following description of certain terms of Oncocyte Corporation (“Oncocyte” or the “Company”) common stock is a summary and is qualified in its entirety by reference to (i) Oncocyte’s Articles of Incorporation, as amended, (ii) Oncocyte’s Certificate of Determination of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, (iii) Oncoc |
|
| March 24, 2025 |
Exhibit 19.1 ONCOCYTE CORPORATION INSIDER TRADING POLICY February 2025 Federal and state securities laws prohibit the purchase or sale of a company’s securities by persons who are aware of material information about that company that is not generally known or available to the public. These laws also prohibit persons who are aware of such material nonpublic information from disclosing this informat |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2025 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| February 10, 2025 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 7, 2025, between Oncocyte Corporation, a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| February 10, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 10, 2025 |
Exhibit 99.1 Oncocyte Prices $29.1 Million Equity Offering Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp., (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into se |
|
| February 10, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 7, 2025, between Oncocyte Corporation, a California corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purcha |
|
| February 10, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 7, 2025 between Oncocyte Corporation, a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| February 10, 2025 |
3,609,755 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-281159 PROSPECTUS SUPPLEMENT (To Prospectus dated August 7, 2024) 3,609,755 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus as well as a securities purchase agreement dated as of February 7, 2025, by and between us and the purchasers named therein, we are offering in a registered direct offering to |
|
| February 10, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Amendment No. 12 to Schedule 13D, dated February 10, 2025, relating to the Common Stock, no par value, of Oncocyte Corporation shall be filed on behalf of the undersigned. Dated: February 10, 2025 Broadwood Partners, L.P. By: Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President Broadwood Capital, I |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 6, 2025 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| January 8, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 2, 2025 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| January 8, 2025 |
Exhibit 10.1 AMENDMENT TO AND WAIVER OF RIGHT TO EXTEND ORIGINAL LEASE This Amendment to and Waiver of Right to Extend Original Lease (“Amendment”) is dated as of December 26, 2024, and entered into by and among ONCOCYTE CORPORATION, a California corporation (“Oncocyte” also referred to as “Tenant”), INDUCE BIOLOGICS USA, INC., a Michigan corporation (“Induce”), and CUSHING VENTURES, LLC, a Califo |
|
| December 9, 2024 |
OCX / OncoCyte Corporation / SMITH PATRICK W Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ONCOCYTE CORPORATION (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 68235C107 (CUSIP Number) December 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-37648 Oncocyte Corporati |
|
| November 12, 2024 |
Exhibit 10.6 Certain information contained in this document, marked by brackets [***], has been omitted pursuant to Regulation S-K, Item 601(b)(10) because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Memorandum of Understanding Oncocyte Corporation (“Oncocyte”) and Bio-Rad Laboratories, Inc. (“Bio-Rad”) (each, a “Party”, and collectively |
|
| November 12, 2024 |
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 Exhibit 99.1 Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 ● Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase ● FDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. |
|
| November 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 12, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of i |
|
| October 24, 2024 |
OCX / OncoCyte Corporation / BIO-RAD LABORATORIES, INC. - SC 13G/A Passive Investment SC 13G/A 1 formsc13gaoctober2024.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Oncocyte Corporation (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| October 22, 2024 |
Oncocyte Corporation 3,461,138 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-282683 PROSPECTUS Oncocyte Corporation 3,461,138 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 3,461,138 shares (the “PIPE Shares”) of our common stock, no par value per share, that were issued pursuant to the securities purchase agreement, dated as o |
|
| October 21, 2024 |
Oncocyte Corporation 15 Cushing Irvine, California 92618 Oncocyte Corporation 15 Cushing Irvine, California 92618 October 21, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences U. |
|
| October 18, 2024 |
As Filed with the Securities and Exchange Commission on October 18, 2024 As Filed with the Securities and Exchange Commission on October 18, 2024 Registration No. |
|
| October 16, 2024 |
As Filed with the Securities and Exchange Commission on October 16, 2024 As Filed with the Securities and Exchange Commission on October 16, 2024 Registration No. |
|
| October 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 Oncocyte Corporation Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, no par value per share Rule 457(c) 3,461,138 (2) $ 3. |
|
| October 15, 2024 |
Exhibit 10.1 AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN ONCOCYTE CORPORATION 1. Purpose; Eligibility. 1.1. General Purpose. The name of this plan is the Oncocyte Corporation Amended and Restated 2018 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable the Company to attract and retain the types of Employees, Consultants and Directors who will contribute to the Compa |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| October 9, 2024 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the common stock, no par value, of Oncocyte Corporation, a Delaware corporation. T |
|
| October 9, 2024 |
OCX / OncoCyte Corporation / SMITH PATRICK W Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ONCOCYTE CORPORATION (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 68235C107 (CUSIP Number) October 2, 2024 Date of Event Which Requires Filing of this Statement Check the appropriate box to designate th |
|
| October 3, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 2, 2024, between Oncocyte Corporation, a California corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchas |
|
| October 3, 2024 |
Exhibit 99.1 |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 2, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| October 3, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 2, 2024, between Oncocyte Corporation, a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| October 3, 2024 |
Oncocyte Signs Leading Transplant Centers in US and Germany Exhibit 99.2 Oncocyte Signs Leading Transplant Centers in US and Germany ● GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volume ● Company clears first stage gate in clinical product development process and has submitted a Q-Sub to the FDA IRVINE, Calif., Oct. 2, 2024 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” o |
|
| October 3, 2024 |
Exhibit 99.3 Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., October 2, 2024 (GLOBE NEWSWIRE) - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today a |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| August 9, 2024 |
Exhibit 1.1 EXECUTION VERSION Oncocyte Corporation Shares of Common Stock SALES AGREEMENT August 9, 2024 Needham & Company, LLC 250 Park Avenue New York, New York 10177 Ladies and Gentlemen: Oncocyte Corporation, a California corporation (the “Company”), confirms as follows its agreements with Needham & Company, LLC (the “Sales Agent”). 1. Issuance and Sale of Shares. (a) On the basis of the repre |
|
| August 9, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-281159 PROSPECTUS SUPPLEMENT (To Prospectus dated August 1, 2024) Up to $7,500,000 Common Stock We have entered into a sales agreement with Needham & Company, LLC, acting in its capacity as the sales agent, or Needham, relating to the offer and sale of shares of our common stock, no par value, from time to time, having an aggregate offering pri |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 9, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 8, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| August 8, 2024 |
Exhibit 10.8 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of June 17, 2024, by and between Oncocyte, Corporation (the “Company”), a California corporation located at 15 Cushing, Irvine, California 92618, and Andrea James (“Executive”). 1. Engagement; Position and Duties. (a) Position and Duties. During the Term (as defined below), the Company agrees to employ Exe |
|
| August 8, 2024 |
Exhibit 99.1 Oncocyte Announces Successful GraftAssureTM Beta Launch and Q2 2024 Results Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (Ex |
|
| August 8, 2024 |
Exhibit 10.7 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of May 20, 2024, by and between Oncocyte, Corporation (the “Company”), a California corporation located at 15 Cushing, Irvine, California 92618 and Ekkehard Schütz, M.D., Ph.D. (“Executive”). WITNESSETH: WHEREAS, Executive currently serves as Chief Science Officer of the Company; WHEREAS, the Company desir |
|
| August 7, 2024 |
Oncocyte Corporation 15 Cushing Irvine, California 92618 (949) 409-7600 August 7, 2024 Oncocyte Corporation 15 Cushing Irvine, California 92618 (949) 409-7600 August 7, 2024 SUBMITTED VIA EDGAR U. |
|
| August 1, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Oncocyte Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registra |
|
| August 1, 2024 |
As Filed with the Securities and Exchange Commission on July 31, 2024 As Filed with the Securities and Exchange Commission on July 31, 2024 Registration No. |
|
| July 12, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 8, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of incorporation) (Commission File |
|
| July 5, 2024 |
Submission of Matters to a Vote of Security Holders, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of incorporation) (Commission File |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of incorporation) (Commission File |
|
| June 17, 2024 |
Oncocyte Appoints Andrea James as Chief Financial Officer Exhibit 99.1 Oncocyte Appoints Andrea James as Chief Financial Officer IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. “We are thrilled to welcome Andrea as we approach the inflection point of commercial lau |
|
| June 4, 2024 |
Oncocyte Corporation 5,419,788 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279350 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated May 23, 2024) Oncocyte Corporation 5,419,788 Shares of Common Stock This prospectus supplement amends and supplements the information contained in the prospectus dated May 23, 2024 (the “Prospectus”) covering resale by the selling stockholders named in the Prospectus of up to 5,419,788 sha |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 30, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction of incorporation) (Commission File |
|
| May 23, 2024 |
Oncocyte Corporation 5,419,788 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279350 PROSPECTUS Oncocyte Corporation 5,419,788 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 5,419,788 shares of our common stock, no par value per share. These 5,419,788 shares of common stock consist of: ● 5,076,900 shares of common stock (the “PI |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 20, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| May 21, 2024 |
Oncocyte Corporation 15 Cushing Irvine, California 92618 Oncocyte Corporation 15 Cushing Irvine, California 92618 May 21, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences U. |
|
| May 17, 2024 |
As Filed with the Securities and Exchange Commission on May 17, 2024 As Filed with the Securities and Exchange Commission on May 17, 2024 Registration No. |
|
| May 15, 2024 |
Exhibit 99.1 ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights ● Announced global commercialization partnership with |
|
| May 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 15, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (E |
|
| May 15, 2024 |
Exhibit 10.6 Certain information contained in this document, marked by brackets [***], has been omitted pursuant to Regulation S-K, Item 601(b)(10) because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. COLLABORATION AGREEMENT This Collaboration Agreement (“Agreement”) is made effective as of April 5, 2024 (the “Effective Date”), by and betw |
|
| May 10, 2024 |
As Filed with the Securities and Exchange Commission on May 10, 2024 As Filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 Oncocyte Corporation Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, no par value per share Rule 457(c) 5,419,788 (2) $ 2. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 22, 2024 |
OCX / OncoCyte Corporation / BIO-RAD LABORATORIES, INC. - SC 13G Passive Investment SC 13G 1 formsc13gapril2024.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 Oncocyte Corporation (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) April 15, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (Exact |
|
| April 16, 2024 |
Exhibit 4.13 DESCRIPTION OF SECURITIES The following description of certain terms of Oncocyte Corporation (“Oncocyte” or the “Company”) common stock is a summary and is qualified in its entirety by reference to (i) Oncocyte’s Articles of Incorporation, as amended, (ii) Oncocyte’s Certificate of Determination of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, (iii) Onco |
|
| April 16, 2024 |
Oncocyte Corporation Clawback Policy Exhibit 97.1 ONCOYTE CORPORATION (The “Company”) CLAWBACK POLICY Adopted November 2, 2023 Introduction The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability in furtherance of the Board’s intention to follow sound corporate governance practices. T |
|
| April 16, 2024 |
Exhibit 10.29 |
|
| April 16, 2024 |
Exhibit 10.28 |
|
| April 16, 2024 |
Exhibit 10.30 |
|
| April 15, 2024 |
OCX / OncoCyte Corporation / BROADWOOD PARTNERS, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 12, 2024 |
Exhibit 99.2 ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights ● Bio-Rad Laboratories, Inc. commercial partnership for |
|
| April 12, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 11, 2024, between Oncocyte Corporation, a California corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase |
|
| April 12, 2024 |
Exhibit 99.1 Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the pu |
|
| April 12, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 11, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| April 12, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 11, 2024, between Oncocyte Corporation, a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 5, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| April 11, 2024 |
Exhibit 99.1 Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay - Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnos |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response...............2.50 FORM 12b-25 SEC FILE NUMBER 001-37648 NOTIFICATION OF LATE FILING CUSIP NUMBER 68235C107 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 22, 2024 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| January 23, 2024 |
Exhibit 99.1 NOW OFFICIALLY AVAILABLE!!! We are excited to announce the official launch of #VitaGraft Kidney! Previously only available through Oncocyte’s Early Access Program, VitaGraft Kidney is now broadly available to transplant professionals upon request. VitaGraft Kidney is a blood-based test that measures donor-derived cell-free DNA (#dd-cfDNA) concentrations post-kidney #transplantation, s |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporatio |
|
| November 9, 2023 |
Exhibit 99.1 ONCOCYTE REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS -Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., November 9, 2023 — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Rece |
|
| November 9, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| November 9, 2023 |
Exhibit 10.3 SUBLEASE AGREEMENT This SUBLEASE AGREEMENT (this “Sublease”), dated as of the 8th day of August, 2023, is made and entered into by and between ONCOCYTE CORPORATION, a California corporation (“Sublessor”), and INDUCE BIOLOGICS USA, INC., a Michigan corporation (“Sublessee”). BASIC LEASE DEFINITIONS NAME OF SUBLESSOR: Oncocyte Corporation SUBLESSOR’S ADDRESS(ES): 15 Cushing Irvine, Cali |
|
| October 10, 2023 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 10, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of |
|
| October 5, 2023 |
Letter of WithumSmith+Brown, PC, dated October 5, 2023 Exhibit 16.1 October 5, 2023 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read Oncocyte Corporation statements included under Item 4.01 of its Form 8-K dated October 5, 2023. We agree with the statements made in paragraphs one through four discussing Oncocyte Corporation’s relationship with WithumSmith+Brown |
|
| October 5, 2023 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 29, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of |
|
| September 20, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 14, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of |
|
| August 28, 2023 |
Press release dated August 28, 2023. Exhibit 99.1 |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 28, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| August 10, 2023 |
Exhibit 99.1 ONCOCYTE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Conference Call on Thursday, August 10, 2023 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., August 10, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarter and Recent Highlights ● Transplant |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 4, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (Ex |
|
| July 24, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF ARTICLES OF INCORPORATION OF ONCOCYTE CORPORATION The undersigned certify that: 1. They are the President and Secretary, respectively, of Oncocyte Corporation, a California corporation, with California Entity Number C3231738. 2. Article FOUR of the Articles of Incorporation of the corporation is amended to read as follows: “FOUR: The corporation is authorize |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 24, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| July 24, 2023 |
ONCOCYTE ANNOUNCES 1-for-20 reverse stock split Exhibit 99.1 ONCOCYTE ANNOUNCES 1-for-20 reverse stock split IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock. The reverse stock split will be effective at 5:00 p.m. Pacific time on July 24, |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 13, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| July 14, 2023 |
Exhibit 10.1 AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT (the “Amendment”), is entered into effective July 13, 2023 (the “Effective Date”) by and between Oncocyte Corporation (the “Company”), a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs (“Executive”). WHEREAS, the Company and Executive previously entered into that certain Amend |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 23, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| June 9, 2023 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of June 6, 2023, by and between Oncocyte, Corporation (the “Company”), a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs (“Executive”). WITNESSETH: WHEREAS, Executive currently serves as President and Chief Executive Officer |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| June 6, 2023 |
Oncocyte Corporation Investor Presentation dated June 6, 2023. Exhibit 99.1 |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (E |
|
| May 11, 2023 |
Exhibit 99.1 ONCOCYTE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS -nearing manufacturing start up of first KITTED product- May 11, 2023 IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023. First Quarter 2023 and Recent Highlights: ● Completed an equity |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 11, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte |
|
| April 14, 2023 |
OCX / Oncocyte Corporation / PURA VIDA INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 4)* Oncocyte Corp (Name of Issuer) Common Stock, No. Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) April 14, 2023 (Date of Event which Req |
|
| April 13, 2023 |
Oncocyte Announces Reduction in Force Exhibit 99.1 Oncocyte Announces Reduction in Force IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforce, which management believes will extend Oncocyte’s cash runway in 2024. “As part of our efforts to bring our cost structure in line with our kitted p |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 12, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| April 12, 2023 |
Exhibit 21 Oncocyte Corporation The following is a list of subsidiaries of Oncocyte Corporation, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary State or Jurisdiction of Incorporation Insight Genetics, Inc. Tennessee Chronix Biomedical, Inc. Delaware Chronix Biomedical GmbH Germany |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (Exact |
|
| April 12, 2023 |
Exhibit 4.12 DESCRIPTION OF SECURITIES The following description of certain terms of Oncocyte Corporation (“Oncocyte” or the “Company”) common stock is a summary and is qualified in its entirety by reference to (i) Oncocyte’s Articles of Incorporation, as amended, (ii) Oncocyte’s Certificate of Determination of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, (iii) Onco |
|
| April 7, 2023 |
OCX / Oncocyte Corporation / BROADWOOD PARTNERS, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 6, 2023 |
45,494,198 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-256650 PROSPECTUS SUPPLEMENT (To Prospectus dated June 8, 2021) 45,494,198 Shares of Common Stock We are offering 45,494,198 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Each share of our common stock that is purchased by any of our officers, directors, employees or consultants, or any entit |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 3, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| April 6, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April , 2023, and is between Oncocyte Corporation, a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 5, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response...............2.50 FORM 12b-25 SEC FILE NUMBER 001-37648 NOTIFICATION OF LATE FILING CUSIP NUMBER 68235C107 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: |
|
| March 31, 2023 |
ONCOCYTE CORPORATION UNAUDITED CONSOLIDATED BALANCE SHEETS (In thousands) Exhibit 99.1 ONCOCYTE REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS and PLANS TO FILE FORM 12b-25 to extend filing date of its form 10-k IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchange Commission regarding its Annual Repo |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| March 2, 2023 |
Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer Exhibit 99.1 Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023. Since being named interim CEO in December, Riggs has successfully led the process o |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of i |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 16, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of i |
|
| February 23, 2023 |
ONCOCYTE CORPORATION UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 ONCOCYTE CORPORATION UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On February 16, 2023, Oncocyte Corporation (“Oncocyte” or the “Company”) completed its sale of 3,188,181 shares of common stock of its wholly-owned subsidiary Razor Genomics, Inc. (“Razor”), which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted |
|
| February 23, 2023 |
ONCOCYTE COMPLETES RAZOR GENOMICS TRANSACTION Exhibit 99.2 ONCOCYTE COMPLETES RAZOR GENOMICS TRANSACTION Feb 22, 2023 Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy IRVINE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has completed the sale of 70% of i |
|
| February 23, 2023 |
Exhibit 2.1 Second AMENDMENT TO STOCK PURCHASE AGREEMENT THIS SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT (the “Amendment”) is adopted as of the 16th day of February, 2023 (the “Effective Date”), by and among Oncocyte Corporation, a California corporation (“Seller”), Dragon Scientific, LLC, a Delaware limited liability company (“Buyer”), and Razor Genomics, Inc., a Delaware corporation (the “Comp |
|
| February 17, 2023 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 15, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (I |
|
| February 13, 2023 |
Exhibit 10.1 TERMINATION AGREEMENT This Termination Agreement (“Termination Agreement”) is made and dated as of the date of the last signature below (the “Effective Date”), by and between Life Technologies Corporation, having a place of business at 5823 Newton Drive, Carlsbad, California 92008 (“LTC”); and Oncocyte Corporation, a California corporation having a place of business at 15 Cushing, Irv |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 7, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| February 13, 2023 |
Exhibit 2.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER, dated as of February 8, 2023 (this “Amendment No. 1”), is entered into by and between Oncocyte Corporation, a California corporation (“Parent”) and David MacKenzie, solely in his capacity as Equityholder Representative (the “Equityholder Repres |
|
| February 3, 2023 |
Exhibit 10.1 |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 30, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 24, 2023 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| December 21, 2022 |
Oncocyte Announces Initiatives to Focus Corporate Strategy Exhibit 99.1 Oncocyte Announces Initiatives to Focus Corporate Strategy IRVINE, Calif., December 16, 2022 (GLOBE NEWSWIRE) ? Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte?s workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has entered into a Stock Purchase |
|
| December 21, 2022 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS This Confidential Separation Agreement and General Release of All Claims, dated December 16, 2022 (the ?Agreement?), is made pursuant to that certain Change in Control and Executive Severance Plan Agreement effective as of October 4, 2021 (the ?Severance Agreement?) entered into by and between Gisela A. Paulsen, MPhar |
|
| December 21, 2022 |
Exhibit 10.2 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS This Confidential Separation Agreement and General Release of All Claims, dated December 16, 2022 (the ?Agreement?), is entered into by and between Douglas Ross (?Employee?) on the one hand, and Oncocyte Corporation (the ?Company?), on the other. Collectively, Employee and the Company shall be referred to as the ?Part |
|
| December 21, 2022 |
Consulting Agreement, by and between the Company and Douglas Ross, dated as of December 16, 2022. Exhibit 10.3 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this ?Agreement?), dated as of December 16, 2022 is hereby entered into by and between OncoCyte Corporation (the ?Company?) and Douglas Ross (the ?Consultant? and, collectively with the Company, the ?Parties?). In consideration of the mutual covenants and promises contained herein, and other good and valuable consideration, the receipt a |
|
| December 21, 2022 |
Exhibit 2.1 Execution Version STOCK PURCHASE AGREEMENT by and between DRAGON SCIENTIFIC, LLC, as Buyer, ONCOCYTE CORPORATION as Seller, and RAZOR GENOMICS INC., as the Company, Dated as of December 15, 2022 TABLE OF CONTENTS: ARTICLE I THE PURCHASE AND SALE 1 1.1 Purchase and Sale 1 ARTICLE II CLOSING 2 2.1 Closing 2 2.2 Closing Deliverables 2 2.3 Frustration of Conditions 3 ARTICLE III TERMINATIO |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 15, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of i |
|
| December 5, 2022 |
Employment Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 Exhibit 10.3 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (?Agreement?) is entered into effective as of December 2, 2022 (the ?Effective Date?), by and between OncoCyte, Corporation (the ?Company?), a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs (?Executive?). WITNESSETH: WHEREAS, the Company desires to continue to employ Executive on the terms and condition |
|
| December 5, 2022 |
Press release announcing Executive Leadership Changes, dated November 30, 2022. Exhibit 99.1 |
|
| December 5, 2022 |
Exhibit 10.4 Amended and restated CHANGE IN CONTROL AND EXECUTIVE SEVERANCE PLAN AGREEMENT This Amended and Restated Change in Control and Executive Severance Plan Agreement (the ?Agreement?) is entered into by and between Josh Riggs (?you? or ?your?) and Oncocyte Corporation (the ?Company?). This Agreement has an effective date of December 2, 2022 (the ?Effective Date?). The Board has authorized |
|
| December 5, 2022 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS This Confidential Separation Agreement and General Release of All Claims, dated December 1, 2022 (the ?Agreement?), is made pursuant to that certain Change in Control Severance Agreement effective as of March 1, 2020 (the ?Severance Agreement?) entered into by and between Ronald Andrews (?Employee?) on the one hand, a |
|
| December 5, 2022 |
Press release announcing Board Appointment, dated November 30, 2022. Exhibit 99.2 |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 30, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of i |
|
| December 5, 2022 |
Consulting Agreement, by and between the Company and Ronald Andrews, dated as of December 1, 2022 Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this ?Agreement?), dated as of December 1, 2022 is hereby entered into by and between OncoCyte Corporation (the ?Company?) and Ronald A. Andrews (the ?Consultant? and, collectively with the Company, the ?Parties?). In consideration of the mutual covenants and promises contained herein, and other good and valuable consideration, the recei |
|
| November 25, 2022 |
OCX / OncoCyte Corp / Norfield Capital LLC - NORFIELD CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Oncocyte Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 68235C107 (CUSIP Number) November 11, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 19, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of i |
|
| November 10, 2022 |
Oncocyte Reports Third Quarter 2022 Financial Results Exhibit 99.1 Oncocyte Reports Third Quarter 2022 Financial Results Irvine, Calif., November 10, 2022 ? Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the third quarter 2022, ended September 30, 2 |
|
| November 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of i |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporatio |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| November 9, 2022 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF ONCOCYTE CORPORATION (the ?Corporation?) ARTICLE I OFFICES Section 1.01 PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at such place within or without the State of California as shall be fixed from time to time by the board of directors, and if no place is fixed by the board of directors, such place a |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 20, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 9, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (Ex |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| August 10, 2022 |
Oncocyte Reports Second Quarter 2022 Financial Results Exhibit 99.1 Oncocyte Reports Second Quarter 2022 Financial Results Irvine, Calif., August 10, 2022 ? Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the second quarter 2022, ended June 30, 2022. |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 28, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 28, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| August 1, 2022 |
Exhibit 99.1 Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) ? Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care |
|
| July 28, 2022 |
OCX / OncoCyte Corp / BROADWOOD PARTNERS, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 15, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| July 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 15, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| July 15, 2022 |
Exhibit 99.1 |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 24, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (E |
|
| May 11, 2022 |
Oncocyte Reports First Quarter 2022 Financial Results Exhibit 99.1 Oncocyte Reports First Quarter 2022 Financial Results Irvine, Calif., May 11, 2022 ? Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the first quarter 2022, ended March 31, 2022. Firs |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 6, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte |
|
| April 19, 2022 |
Exhibit 1.1 26,266,417 SHARES of Common Stock and 26,266,417 Warrants TO PURCHASE 13,133,208.5 SHARES OF COMMON STOCK of ONCOCYTE CORPORATION UNDERWRITING AGREEMENT April 13, 2022 BTIG, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o BTIG, LLC 600 Montgomery Street, 6th Floor San Francisco, California 94111 Ladies and Gentlemen: The undersigned, OncoCy |
|
| April 19, 2022 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT oncocyte corporation Warrant Shares: [?] Initial Exercise Date: April 19, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ? |
|
| April 19, 2022 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 13, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 001-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| April 19, 2022 |
ONCOCYTE CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Exhibit 99.2 ONCOCYTE CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) ? Oncocyte Corporation (Nasdaq: OCX), (?Oncocyte? or the ?Company?), announced today the pricing of an underwritten public offering of 26,266,417 shares of its common stock, together with warrants to purchase up to an aggregate of 13,133,208.5 shares o |
|
| April 19, 2022 |
ONCOCYTE CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Exhibit 99.1 ONCOCYTE CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) ? Oncocyte Corporation (Nasdaq: OCX), (?Oncocyte? or the ?Company?), announced today that it has commenced an underwritten public offering of shares of its common stock, together with warrants to purchase additional shares of its common stock. The Compan |
|
| April 18, 2022 |
OCX / OncoCyte Corp / Halle Special Situations Fund LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oncocyte Corporation (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 68235C107 (CUSIP Number) April 18, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| April 18, 2022 |
11,765 Shares of Series A Convertible Preferred Stock 7,689,542 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-256650 PROSPECTUS SUPPLEMENT (To Prospectus dated June 8, 2021) 11,765 Shares of Series A Convertible Preferred Stock 7,689,542 Shares of Common Stock We are offering 11,765 shares of our Series A Convertible Preferred Stock, or the ?Series A Shares,? pursuant to this prospectus supplement and the accompanying prospectus. The Series A Shares ar |
|
| April 18, 2022 |
Joint Filing Agreement (filed herewith). EXHIBIT 99.1 JOINT FILING AGREEMENT April 18, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereund |
|
| April 15, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-256650 PROSPECTUS SUPPLEMENT (To Prospectus dated June 8, 2021) 26,266,417 Shares of Common Stock 26,266,417 Warrants to Purchase Common Stock 13,133,208.5 Shares of Common Stock Issuable upon Exercise of the Warrants We are offering 26,266,417 shares of our common stock and 26,266,417 warrants to purchase up to 13,133,208.5 shares of our commo |
|
| April 15, 2022 |
OCX / OncoCyte Corp / BROADWOOD PARTNERS, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 13, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April , 2022, between Oncocyte Corporation, a California corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| April 13, 2022 |
SUBJECT TO COMPLETION, DATED APRIL __, 2022 Filed Pursuant to Rule 424(b)(5) Registration No. 333-256650 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 001-37648 27-1041563 (State or other jurisdiction of incorporation) (Commission F |
|
| April 13, 2022 |
Exhibit 3.1 CERTIFICATE OF DETERMINATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES a CONVERTIBLE PREFERRED STOCK OF Oncocyte corporatiOn The undersigned, Ronald S. Andrews and Peter Hong, do hereby certify that: I. They are the President and Secretary, respectively, of Oncocyte Corporation, a California corporation (the ?Corporation?) with Entity Number 3231738. II. The following resolution |
|
| April 13, 2022 |
Exhibit 99.1 Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock Irvine, Calif. - (GLOBE NEWSWIRE) April 13, 2022? Oncocyte Corporation (Nasdaq: OCX), (?Oncocyte? or the ?Company?), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions t |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 8, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| March 11, 2022 |
Exhibit 21 Oncocyte Corporation The following is a list of subsidiaries of Oncocyte Corporation, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary State or Jurisdiction of Incorporation Insight Genetics, Inc. Tennessee Razor Genomics, Inc. Delaware Chronix Biomedical, Inc. Delaware Chronix Biomedical GmbH Germany |
|
| March 11, 2022 |
Exhibit 4.11 DESCRIPTION OF SECURITIES The following description of certain terms of Oncocyte Corporation (?Oncocyte?) common stock is a summary and is qualified in its entirety by reference to (i) Oncocyte?s Articles of Incorporation, as amended, (ii) Oncocyte?s Amended and Restated Bylaw, and (iii) the California General Corporation Law. Common Stock The Oncocyte Articles of Incorporation curren |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (Exact |
|
| March 11, 2022 |
Exhibit 10.43 EXECUTION VERSION Certain information contained in this document, marked by brackets [***], has been omitted pursuant to Regulation S-K, Item 601(b)(10) because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. COLLABORATION AGREEMENT This Collaboration Agreement (?Agreement?), is made effective as of January 13, 2022 (the ?Effect |
|
| March 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 10, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| March 10, 2022 |
Exhibit 99.1 Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update DetermaRx Revenues and Test Volume Grew 104% and 54%, respectively, in Q4 versus Q3 2021 Development and Co-Marketing Agreement with Thermo Fisher Scientific to Provide Platform and Channel Partner for Delivering Determa Product Line to Laboratories in Europe and other International Mark |
|
| January 18, 2022 |
Exhibit 99.1 News Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology Collaboration extends global reach for Thermo Fisher?s rapid next-generation sequencing technology IRVINE, Calif., January 18, 2022 ? Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by provi |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 13, 2022 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| December 14, 2021 |
Exhibit 99.1 |
|
| December 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 14, 2021 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of i |
|
| December 8, 2021 |
Exhibit 10.1 Addendum No. 2 December 05, 2021 The Exclusive Sublicense Agreement in the PRC Territory (the ?Agreement?) was entered into by and among Razor Genomics, Inc. (?Razor?), Oncocyte Corporation (?Oncocyte?), Encore Clinical, Inc. and Burning Rock Biotech Limited (?Burning Rock?), on December 14, 2020, and an addendum (?Addendum No.1?) was executed on June 30, 2021 to provide clarification |
|
| December 8, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 5, 2021 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| December 8, 2021 |
Exhibit 99.1 Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of ?DetermaRx? in China Companies complete second and most critical of three steps in Technology Transfer Oncocyte receives $2M milestone payment Irvine, Calif., December 8, 2021 ? Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient ou |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporatio |
|
| November 9, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2021 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| November 9, 2021 |
Exhibit 99.1 Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other biomarkers DetermaIO data in Triple Negative Breast Cancer published in a peer reviewed journal and co |
|
| November 4, 2021 |
Exhibit 99.1 Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has consistently proven to be more precise at identifying patients who are immunotherapy responders including t |
|
| November 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 4, 2021 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| October 27, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 27, 2021 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of in |
|
| October 27, 2021 |
Exhibit 99.1 Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe Oncocyte?s recently acquired Therasure Transplant Monitor facilitates fast and acc |
|
| October 7, 2021 |
Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer Exhibit 99.1 Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer Irvine, Calif., October 7, 2021 ? Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced the appointment of Gisela A. Pau |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 4, 2021 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| October 7, 2021 |
Exhibit 10.1 CHANGE IN CONTROL AND EXECUTIVE SEVERANCE PLAN AGREEMENT This Change in Control and Executive Severance Plan Agreement (the ?Agreement?) is entered into by and between Gisela A. Paulsen, MPharm (?you? or ?your?) and Oncocyte Corporation (the ?Company?). This Agreement has an effective date of October 4, 2021 (the ?Effective Date?). The Board has authorized the Company to enter into th |
|
| September 24, 2021 |
OCX / OncoCyte Corp / BROADWOOD PARTNERS, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| September 20, 2021 |
Exhibit 99.1 Oncocyte Announces Oral Presentation of New Data on Its DetermaIO? Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response Trial Investigators found DetermaIO outperformed 80 other immune related signatures in TNBC Irvine, Cal |
|
| September 20, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 20, 2021 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 1-37648 27-1041563 (State or other jurisdiction (Commission (IRS Employer of |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-37648 Oncocyte Corporation (Ex |
|
| August 10, 2021 |
Exhibit 99.1 Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update DetermaRx Q2 Sample Volume Grows 23% over Q1 2021 Potential pan-cancer utility of DetermaIO strengthened by data in breast, lung, bladder and renal cell cancer, validating the test in all four tumor types evaluated; upcoming oral presentation of randomized clinical trial in TNBC at ESMO Chronix acquis |
